Lilly assumes development of Transition's diabetes drug candidate

06/19/2013 | Wall Street Journal, The

Eli Lilly and Co. is exercising a $7 million option to obtain all development and marketing rights to Transition Therapeutics' experimental type 2 diabetes drug TT-401. Transition could get around $240 million more in milestone fees plus royalties if the drug reaches market. "We look forward to continuing the development of TT-401, as it supports our strategy of offering a broad portfolio of therapies for people with diabetes," Lilly official David Moller said.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA